Egypt launches EIPICO 3 biopharma plant in 10th of Ramadan

EIPICO 3 10th of Ramadan biopharmaceutical plant Egypt drug manufacturing

On 26 July 2026, Egypt’s Minister of Health and Population Dr. Khalid Abdelghaffar inaugurated the EIPICO 3 biopharmaceutical manufacturing facility in the industrial city of 10th of Ramadan. The plant, owned by the Arab Group for Pharmaceutical Industries and Medical Supplies (Akdima), represents an investment of more than $100 million and occupies 10 500 m².

It is the first modular‑construction biopharma plant in Egypt and the Middle East, capable of producing full‑process biologics from genetically modified cells to final drug products. The factory will manufacture 14 products targeting cancer, blood disorders, fertility, kidney disease and anaemia, using bioreactors, preparation zones and automated packaging lines supplied in partnership with Swedish firm Pharmadule.

EIPICO operates three sites totaling 130 500 m², 59 production lines, and an annual output of 327 million units. In the previous year the group recorded 10.8 billion Egyptian pounds in production, 9.3 billion in sales, and exported to over 60 countries, accounting for 25 % of Egypt’s drug exports and 30 % of its exports to Africa.

Entities: 10th of Ramadan City · Acdima Group · Arab Group for Pharmaceutical Industries and Medical Supplies (Akdima) · Dr. Khalid Abdelghaffar · EIPICO 3 · EpiCo 3 · Khaled Abdel Gafar · Ministry of Health and Population (Egypt) · Pharmadule · Pharmadule AB

Claims

What the coverage asserts, and how well corroborated each claim is across sources.

[● 4 SOURCES] Production lines include bioreactors, preparation zones and automated packaging lines using modular construction technology in cooperation with Swedish firm Pharmadule. (6ded41b8, 694ff12b, 34da785a, 52d6fcda)
[● 4 SOURCES] The Egyptian Minister of Health and Population inaugurated the EIPICO 3 factory in the city of 10th of Ramadan. (6ded41b8, 694ff12b, 34da785a, 52d6fcda)
[● 4 SOURCES] The factory will produce 14 biopharmaceutical products for cancer, blood diseases, fertility, kidney disease and anaemia. (6ded41b8, 694ff12b, 34da785a, 52d6fcda)
[● 4 SOURCES] The plant is the first modular‑construction biopharma facility in Egypt and the Middle East that produces biologics from genetically modified cells to final products. (6ded41b8, 694ff12b, 34da785a, 52d6fcda)
[● 4 SOURCES] In the previous year the company's production value was 10.8 billion Egyptian pounds, sales 9.3 billion, exporting to over 60 countries with $60 million in exports, representing 25 % of Egypt’s drug出口 (6ded41b8, 694ff12b, 34da785a, 52d6fcda)
[● 4 SOURCES] Investment in the plant exceeds $100 million and the facility covers 10 500 m². (6ded41b8, 694ff12b, 34da785a, 52d6fcda)
[● 4 SOURCES] EIPICO operates three factories totaling 130 500 m², 59 production lines, producing 425 pharmaceutical products with an annual output of 327 million units. (6ded41b8, 694ff12b, 34da785a, 52d6fcda)
[● 4 SOURCES] The factory is owned by the Arab Group for Pharmaceutical Industries and Medical Supplies (Akdima). (6ded41b8, 694ff12b, 34da785a, 52d6fcda)